Raymond James Financial
EDSA icon

Raymond James Financial’s Edesa Biotech EDSA Stock Holding History

Raymond James Financial’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29
Closed -$59 – 5477
2025
Q2 		$59 Buy
+29
New +$62 ﹤0.01% 6876

Other funds holding EDSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Raymond James Financial's EDSA Position: Q3 2025 in Review

Raymond James Financial sold out of Edesa Biotech (EDSA) in Q3 2025, closing a stake of 29 shares — an estimated $59 sold.

Raymond James Financial first reported a position in EDSA in Q2 2025 and held it in 1 quarter. The position peaked at $59 in Q2 2025. 23 funds tracked by Wall St. Rank hold EDSA as of Q3 2025.

  • Raymond James Financial reported no remaining Edesa Biotech position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 29 Edesa Biotech shares in Q3 2025, an estimated $59.
  • Raymond James Financial first reported a position in Edesa Biotech in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Edesa Biotech position peaked at $59 in Q2 2025.
  • 23 funds tracked by Wall St. Rank held Edesa Biotech as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.